Dr. Jay Bhattacharya, Director of the National Institutes of Health and Acting Director of the Centers for Disease Control and Prevention, joins PragerU CEO Marissa Streit to discuss how the COVID-19 response became politicized, why public trust in science and public health institutions declined, and his efforts to remove DEI initiatives and other political priorities from the NIH. Dr. Bhattacharya reflects on the criticism he faced for opposing lockdowns and vaccine mandates during the pandemic and outlines his vision for returning the NIH to its core mission: funding world-class biomedical research that advances scientific innovation, improves health, and extends human longevity.
Dr. Jay Bhattacharya joins Marissa Streit to discuss COVID, NIH reform, DEI in science, vaccine mandates, and restoring medical innovation.
Chapters: 00:00 Dr. Jay Bhattacharya on COVID, Censorship, and the NIH 01:57 Why Dr. Jay Spoke Out During COVID 04:07 Why Public Health Cannot Just “Move On” 06:50 Can Americans Trust the NIH Again? 10:00 How Do You Reform a $50 Billion Institution? 11:05 How Politics Entered the NIH 15:14 Is the NIH Banning Words and Blocking Research? 17:30 Is the NIH Funding Safe Science Instead of Breakthrough Ideas? 22:10 How Dr. Jay Is Changing NIH Grant Funding 26:16 Is Peer Review Broken? 30:08 Who Gets to Decide What Is True in Science? 33:45 Why Replication Matters 35:31 How the NIH Plans to Fix the Replication Crisis 39:07 Is America Still Leading Biomedical Innovation? 42:15 Cancer Research, Immunotherapy, and Medical Breakthroughs 44:01 Gene Editing, Sickle Cell, and the Future of Cures 47:12 How Should Parents Think About Vaccines After COVID? 50:04 Why Do We Still Vaccinate for Rare Diseases? 52:00 Can Public Health Rebuild Trust with Parents? 54:19 What About Peptides and Right to Try? 55:37 What Would Success at the NIH Look Like? 56:08 Final Thoughts
Dr. Jay Bhattacharya, Director of the NIH, discusses his mission to depoliticize public health and restore institutional trust following the COVID-19 pandemic. He outlines systemic reforms to the NIH, focusing on eliminating partisan agendas, combating scientific stagnation, and addressing the replication crisis to prioritize genuine biomedical innovation and human longevity.
The collapse in trust in public health continues to this day.
We still are in the COVID hangover period.
Grappling with that is the central question of this age.
You're attacked from so many directions.
We just want you guys to do good for us.
Can that be done?
What came before was politicization
and what we're doing now is depoliticization.
There is a claim that you have some secret ward bank,
235 plus wards, that if a research paper is submitted
with these wards, it gets flagged.
Is it true?
Is there a secret ward bank?
I am deeply against banned ward lists.
I don't believe in them.
I will not have my institution embrace them.
Science should be about being disruptive.
We want the Galileos.
We want the disruptors.
I care if the project disrupts science for the good,
if it results in better cures and treatments
and better health for people.
Dr. Jay Bhattacharya.
Okay, Jay.
Jay, I know you want me to call you Jay.
Okay, Jay.
What a great honor it is to sit with you here.
I think it's actually surreal as we were sitting down
it's such a testament to America, right?
Americans and our bravery and our morality.
The fact that we have watched you being attacked
as you tried to defend us against the COVID onslaught,
if I may call that.
And you were attacked from so many directions
and now you're the head of this massive NIH.
I sit back and I am in awe of this country.
We just celebrated the 4th of July
and I was just thinking about how did I get to this place?
I mean, I arrived in this country as a three-year-old
and we were immigrants.
I went to public schools
and then I found myself as a professor at Stanford.
2020, I thought I had a nice career
and I realized that that career meant nothing
when I saw what was happening during the COVID pandemic.
I saw people locked away,
kids not being allowed to go to school,
huge, huge sort of violations of basic standards
of public health.
When the COVID vaccine came out,
I protested against the mandates
and that led me to get canceled, as you said,
attacked by lots and lots of folks,
some of whom I respect and love
but they just lost their way.
I thought my career was over
and now I'm the director of the National Institute of Health.
Yeah, it is amazing.
Where do you get that?
Where do you get your values from?
Because many physicians may have agreed with you
quietly, silently, but you were pretty outspoken.
Well, I'm a Christian
and my faith is tremendously important to me.
I don't believe my purpose is to put lines on my CV
or to get accolades and awards.
My purpose is to serve others, to love others.
And my research before the pandemic
was on vulnerable populations.
I studied poor people.
I studied disabled people.
I studied children.
I studied people who faced starvation
and I studied those vulnerable populations
because I wanted to make a difference
in the lives of people who are really the least of us
or are in tough situations.
I believe very firmly in science and math and economics
and other statistics to make a difference
if they're applied properly to these.
And so when the pandemic happened
and I was subject to some crazy attacks,
I had to decide.
I could have just stayed silent
and I knew that if I stayed silent or just backed up,
then all my friends that were in academics
would just forgive me and I could go back in
and I'd be fine.
But I couldn't do it because my obligation
to the people I studied was more important
than my obligation to making my career advance.
And I think that's really the bottom line.
It's like, what do we do this job for?
It's not for ourselves.
You know, now that the COVID era is somewhat over,
and I say somewhat because many of us
are still paying the price for what was done to us
with the lockdowns.
Many of us who have little kids
who are behind on education and all kinds of major issues.
So the COVID era is somewhat over.
Do you feel like your colleagues ever walked up to you
and said, you know, Dr. J, we were wrong.
You were right.
Or we're sorry that we behaved in the way that we behaved.
Did you ever get some sense of either an apology
or even an act of remorse?
From some people.
But I mean, I think that most people,
most scientists and people in public health,
they just want to move on from the pandemic.
Because I mean, I think most of them,
many of them, if they're honest,
recognize the colossal failures that happened
of science and public health during that era.
And they recognize that, as you say,
the harm are still continuing.
Like kids that were out of school for,
some kids are out of school for up to two, three years.
They're way behind.
We still have the economic hangover.
All the people that suffered from vaccine injuries
that are unacknowledged.
And the collapse in trust in public health,
that continues to this day.
So we still are in the COVID hangover period.
And so grappling with that
is the central question of this age.
It's trying to understand how we can learn those lessons.
A lot of the public health establishment,
a lot of the scientists just want to move on.
They want to say, okay, that was then.
This is now.
Just go back to old times.
I don't think that we can do exactly that.
I do believe very fundamentally in reform.
We have to do something about,
but we have to do something about the fact
and have to really learn the lessons of the pandemic era.
Yeah, well, I think it's really unfair to expect us
to just want to move on because,
as we mentioned, we're still suffering.
And I think the fact that there hasn't been
an acknowledgement from the general scientific community
that something was done,
whether it was nefarious or accidental or maybe hubris,
something was done.
And I'm curious,
now that you're in this position here at the NIH,
what do you think is fair to expect of the institutions?
I don't want to have unfair and unreasonable expectations.
And by the way, I completely recognize
that we can't maintain a country
that doesn't believe in any of its institutions, right?
If you understand communism,
and there's a document that came out in 1958,
it was translated in the 60s by Leon Klausen,
who said that the 45 ways to take America down,
the naked communists,
45 ways to take America down
is to create complete disbelief in Americans' institutions.
And so we don't want that, right?
Dr. Jay, we don't want to be living in a country
where we don't trust any of our institutions.
We need to regain our trust in our institutions,
and we need to regain it very, very fast
because the communists are coming after us.
And so what do you think is reasonable to expect?
What should be done so that when we look at the NIH,
we can say, okay, we trust you guys.
Yeah, I mean, I think first we have to go back.
So we've been talking about the failures
during the pandemic,
but the fundamentals, actually,
of the scientific institutions of this country,
including the NIH, actually, in many ways are incredible.
If you go back to the history of the NIH a century or more,
almost every single major biomedical research advance
of the past century has at its heart, to some degree,
some investment by the NIH.
Huge numbers of cures,
almost every drug that's on the market
or pharmaceutical that's on the market
has the basic biology that we know,
the Nobel Prize winners that we funded.
All of these are NIH accomplishments.
In a sense, the NIH is a sound institution,
and it's an institution that serves the American people
and the world very well, right?
The idea is that who's going to invest
in learning fundamental basic things
that you can't monetize necessarily,
but are nevertheless fundamental for our health, right?
It has to be an institution like the NIH.
In fact, it has to be the NIH.
So it's a fundamentally sound institution.
The problem is that, there's several problems, many problems,
but the problem is that there's scientific hubris,
there's pharmaceutical monetary interests,
there's the pandemic hangovers we've been talking about,
all of which I think cloud
the fundamental soundness of the NIH.
My job, as I see it, is to address those problems.
And maybe I don't talk enough about how important the NIH is,
and I probably should do more of that,
because the reason I want to reform it
is because it's a worthwhile institution.
It can help, it's the core of making America healthy again.
If we don't have real knowledge
about what makes America healthy again,
how can we get healthy?
Yeah, it makes total sense.
We can't give up on our institutions, right?
And so we do need you guys to be successful
and we want to be able to trust you, right?
And so I completely agree.
And I also think we need to be reasonable
about our expectations.
And I fully admit, I have unreasonable expectations.
I'm known for having unreasonable expectations.
It's why we've created PragerU and we've grown so much.
But as I was driving in here today, I said to myself,
you've only been on this job for 15 months, right?
That's not a long time.
I have still employees who've been around for 15 months
and I still think of them as someone new.
And so what do you think is reasonable?
What do you think is reasonable?
You know, the Maha community is very eager.
They want to see massive change.
And we'll talk about some of the changes that I've collected
and things that they've been very concerned about.
But I also want to mitigate the expectations
of what could one expect?
What kind of change can we expect you to do?
Let's start with one example.
We don't want science to be politicized.
We just want you guys to do good for us.
Can that be done?
Yeah. Okay.
So first, let me just say,
it's a $50 billion institution, right?
So it's a huge, huge organization with 20,000 employees
and almost every single university
or research center in the country
receives some funding from us,
relies on funding from us.
And the policies that it has are,
I mean, they go back decades, right?
Some of them.
So shifting, it's like moving a big ship.
It's going to take a little while.
The key thing is the sense of mission and purpose
that you give to the institution like this
so that you have the right direction.
I mean, I've watched Dennis Prager for a long time,
decades actually.
I think I first heard of him in 2005.
But the point is that that kind of consistent
pointing in the same direction,
where there's a sense of mission
is how you change an institution like this.
And it doesn't happen overnight.
So let me just give you an example
in response to your question about politicization.
So just bluntly, the NIH,
although the vast majority of its mission
is to fund biomedical research
that improves the health and longevity
of the American people and the world, in fact,
it had over the past 15 years,
had incorporated some political elements.
During the pandemic,
it became in many ways explicitly political.
Some of the sort of press criticisms
you're seeing of the NIH now
is they're saying that we're like,
we made the NIH political.
They're missing the big picture,
which is that over the last decade and a half,
the NIH had entered politics
in an explicit partisan way.
And I think their emails
from former directors of the NIH
essentially more or less strongly hinting
about who they did or didn't want
in the White House, for instance.
I think another example of that
is the commitment that the NIH had
to DEI research.
The idea was that you had to do DEI research
as a way to improve
the health of minority populations
who actually suffer from many, many health issues
that are more acute than other populations, right?
So what I've been doing as NIH director
is removing a lot of this politicization, right?
So we've gotten rid of, as best we can,
all of our support for these DEI initiatives.
But now, that looks like politicization
because I have to say,
look, you're not allowed to do these DEI initiatives.
That's a political stance.
I'm doing the politics,
now you're considered political.
I look political, right?
Which is really quite unfair, right?
I think the key thing is that
if the NIH focuses on its essential mission,
biomedical research that improves
the health and longevity of people,
that's kind of, in a sense,
that has political ramifications.
If we're living longer, healthier lives,
we spend less on Medicare and Medicaid.
We worry less about social security being there
because we can live a longer time
being healthy and in a workforce.
We can educate our kids better.
Those have tremendous political implications.
Those are like good, natural,
organic political implications
of us achieving our mission
of improving health and longevity,
right, through biomedical research.
But a narrow partisan political mission, right?
Let's use DEI to solve
all the race problems in the country.
Well, first, that doesn't actually
end up helping minorities.
If you look at life expectancy of minorities
over the last 15 years, it's flatlined.
From 2010 to 2019,
there was almost no improvement
in minority longevity.
Actually, this is true for every group
in the United States.
There was a collapse in life expectancy
during the pandemic,
and only now we're getting back
to roughly where we were in 2019.
There's no evidence that this commitment
to this politicized DEI agenda
actually helped minority health at all.
What I'm interested in doing
is doing research that actually does improve
the health of minority populations
as well as everybody else.
That, to me, is depoliticization of the NIH.
It's unfortunate that the NIH
had become politicized in this way,
and it's unfortunate that a lot of the press
doesn't seem to recognize that
what came before was politicization,
and what we're doing now is depoliticization.
Yeah, well, since you mentioned
the attacks on you,
I'm not going to mention the publication
because I don't want to give them air.
But there is a claim that you have
some secret word bank
where there are 235-plus words
that if a research paper is submitted
with these words,
it gets flagged somehow
for some sort of review
and maybe even a rejection of the research
because it's laced in DEI.
So can you just be transparent with me and clear?
Is it true?
Is there a secret word bank?
So there's no secret word bank at all.
So first of all,
I've ordered throughout the NIH
that there never be a banned word list, right?
I was subject to censorship.
The blacklist?
Yes, like a blacklist by Twitter
of the order of the Biden administration.
Essentially, their entire censorship regime
was about banned words.
And so I am deeply against banned word lists.
I don't believe in them.
I will not have my institution embrace them.
Now, but in order to decide
whether something is good research
or just politicized DEI,
you do need to have tools
to identify potentially what they are.
And so people use tools
which have words in them, right?
Those tools then may identify a grant
and then you have a human review
to decide is this good science or not.
Often what ends up happening
is you identify a grant
that has some,
that looks like it might be DEI.
You read the application
and it turns out it's not DEI.
People just put it up there
because that's how you used to be able
to get grant applications.
In order to get a grant,
you have to pretend to be doing DEI
and then you'd secretly be doing
good science underneath.
And so we just negotiate with the scientists
who are like relieved
to remove the political nonsense
so they can focus on what they're good at,
which is science.
So there are tools to identify
which grants are out there
that are the grant applications
to look for scientific opportunities,
remove the politicization of it.
But that's very different
than a banned word list.
Just because you say a word
doesn't mean that you're not
going to get an NIH grant.
You have to say lots of great words
in order to get an NIH grant.
Yeah, you would hope.
So much of what you do
is actually decide how to allocate funding
for research that is worth researching.
And one of my fears
is that oftentimes researchers
will submit for grants
that they think that they're more likely
to receive funding for
because it's safe, right?
But science should be about
being disruptive, right?
I mean, we want the Galileos.
We want the disruptors.
And I'm curious,
how are you able to shift
the old ways of giving grantees
the marching orders
to play with the consensus
rather than break the consensus
and actually come up with new?
Yeah, I mean, I think...
So let me flesh that out
because there's actually an empirical case
for what you just said
that I researched before
I became NIH director.
And it's actually very surprising, right?
So if you do an analysis,
okay, let's take all of the words
that were published
in every single paper
in biomedicine in 1940.
Just take them, list them out,
every single word in every single paper
and, you know, or word phrases
and just list them all.
And then you do the same thing
in 1941 and subtract off
all the words you found in 1940.
What you're left with
are all the new words
and word phrases
that were introduced in 1941.
You do this for every single year,
1942, 43, all the way up to the present.
And you have a history of biomedicine
that's based on just the words
that were published in the literature,
in the biomedical research literature.
We did this.
Me and my colleague, Nico Pakkalen,
when I was a Stanford professor,
we did this.
And what you do then
is you go back to the papers
and ask how new are the ideas
in every single paper.
Real easy to do
because you just have a set of words
introduced and you know
every year they were introduced.
From that, you can do
all kinds of interesting things, right?
So for instance,
how old were the ideas
for NIH-supported researchers?
How old were they in the 1980s?
How old were they in the 2000s,
2010s, and so on?
It turns out that the NIH
has become exactly, as you say,
more and more conservative
in a bad way over the last 30 years
and then 40 years.
In the 1980s,
the NIH-funded researchers
were publishing papers
that were like with ideas
that were zero, one, or two years old
at the bleeding edge.
By the 2000s, 2010s,
NIH was funding researchers
that were publishing research
that typically were
seven or eight-year-old ideas
instead of zero-year-old ideas.
There's lots of reasons for this.
Partly that it coincides
with a collapse in support
for young researchers
over the last three, four decades.
Now it takes much longer
for young researchers
to be able to get large NIH grants.
Wait, why?
Don't we want that kid with the hoodie
and the backpack
to invent the next great thing?
It's usually the young people
with those young minds.
Why wouldn't the NIH support that?
I mean, I think there's
small-p politics behind it, right?
So if you're a successful researcher
and you've had a great
30s and 40s
and you've developed
these new ideas,
you've developed a reputation,
it's much easier to get large grants
even though that your next idea
isn't as disruptive
as they were when you were younger.
Because it's not what you know,
it's who you know?
Well, it's just easier.
So just bluntly,
we have a very, very high level.
My job is to look at
100,000 applications
that we get every year.
I can't personally do it,
that's why you have 20,000 people.
And then we have to pick 10,000 of them
to fund, right?
Which of the 10,000
from the 100,000 will we pick?
So we have scientific peer review panels
that read every single application, right?
So every application gets three reviewers
to look at them.
At some point during the 2000s
and 2010s,
what would happen is
that in order to be a reviewer,
a permanent reviewer
on the NIH study section,
you had to have already have
a large NIH grant.
Well, if you read,
suppose you're a reviewer
of a grant application,
you're reading it,
you go, gosh,
this young person has an idea
that would overturn my idea.
Oh no.
You're going to give it a bad score, right?
You recognize it's innovative,
but you're like,
oh, this will never work.
And you may not be doing that
as something bad,
you're just,
this is just how you think
about the world, right?
In order to create the space
for new ideas,
you have to have a culture
and institutions and incentives
to allow that to happen.
And increasingly over the last
three or four decades,
American biomedical sciences,
especially the NIH,
became more restrictive.
It emphasized,
will this project work over
will this project disrupt
in decision-making over grants?
And it's just, again,
small p politics
of scientific politics,
not partisan politics
that led to this.
What we've done
in the last 15 months
is change the way
that we decide
which of the grants are funded.
It's called the Uniform Funding Strategy.
I'm kind of not really good at marketing,
so it's kind of a boring sounding title,
but let me just say.
But it's actually revolutionary.
Okay, so first of all,
we still get the 100,000 applications.
We still have the peer reviewers,
three peer reviewers
read every single one of them.
We still have fantastic
peer review committees.
We've started to inject
more young people into them
so that they have a fair chance.
They get to the reviews
as well as submit the articles.
The peer reviewers,
they give the applications
sort of two major scores, right?
They just say,
they say, okay,
can this project work?
Right, that's a method score.
And then they give
another score on innovation.
Well, is this a disruptive project?
The overall score
is sort of a mishmash
between those two scores,
methods and innovation.
There's some other criteria,
but those are the two major ones.
It used to be the case
for many NIH institutes
that they would take the overall scores
for all these 100,000 applications
and rank them best to worst
from the peer reviewers.
And then based on how much money
there was available,
they would throw it to a line,
maybe 10, 8, 10, 11%
of the applications
would be above the line
and everything else wouldn't get funded.
Was the ranking based
on how likely they are to succeed
or how likely they are to disrupt?
That's it.
The overall score
very strongly correlates
with how likely it is to succeed
and much less strongly correlated
how likely they are to disrupt.
And so when you did the ranking,
you picked things
that were going to produce
an article in some period
you journal,
but it would just be a tiny advance
relative to the.
It's like only safe bonds
with very low yield
would get an investment,
but it's very un-American actually
because it goes against innovation.
I mean, so I used to teach again
at Stanford and Silicon Valley,
the ethos in Silicon Valley
venture capital is
you have a portfolio of projects,
49 of them fail
and the 50th is Google.
You're a great portfolio manager.
And the people
who did those 49 projects failed,
they're not failures, right?
If they had a constructive,
they understood why they failed,
then they can get a second chance, right?
At the NIH,
we've shifted toward a strategy
that's more like that now
for deciding what to get funded.
Now we still do their peer review,
but now we have the people
who decide what the portfolio looks like,
the institute directors,
they are encouraged very strongly
to look at the entire review,
not just the overall score,
which correlates with,
will this succeed?
Will this get a paper in some journal?
I fundamentally don't care
if a project gets a paper in a journal.
I care if the project disrupts science
for the good,
if it results in better cures and treatments
and better health for people.
Well, I'd imagine you can use AI
for a lot of this streamlining.
AI can help,
but fundamentally you need somebody
who can look at it and say,
yeah, you need your...
I mean, AI is like a tool
to help with that.
You still need someone to look and think.
And so you have a portfolio then
that includes disruptive ideas.
Not sure if they're going to work,
but they're worth trying out, right?
And the goal of the portfolio
is not to make a gazillion dollars
like a venture capital fund.
It's the goal of the portfolio
is to disrupt science.
It's to improve health.
It's to achieve the mission of the NIH,
which is to improve health and longevity.
And that's how people
are going to get judged here.
It's not,
did you produce a scientific paper
and win a Nobel prize,
as fun as that might be.
It's, did you actually improve
the lives of people that were...
I mean, taxpayers give us $50 billion.
It's a great responsibility.
And we have to return that
and turn it into better health
and better lives for people.
That's our job.
Yeah. I mean, your ROI
is not return on investment.
It's really return on influence, right?
Can you influence the healthcare system
for the better?
And so you use the words peer-reviewed,
which triggers me,
actually brings me back
to this shouting match
that I had with one
of my brilliant surgeon friends
during, I think it was during the lockdowns,
where he kept quoting peer-reviewed journals.
And I just said, I just,
who are these peers
that are reviewing in these journals?
I don't trust them anymore now.
I grew up hearing that, well,
you would have this journal
and it's very respected
and you should trust it
because it's peer-reviewed,
but they have made so many mistakes
and never showed remorse.
And so I'm not sure
if they're to be trusted
or are they a mafia
that all peer-reviews each other.
Can you help somebody like me
just discern how to think
about the peer-reviewed journals?
Sure. Okay.
So I, again, I was,
I keep saying I was professor
as if I'm bragging,
but I just,
because it helps me like establish
that I actually know something about this.
And in fact, I've,
myself have conducted peer-reviews
of thousands of papers, right?
So the way it works is
you're a, you're a scientist, right?
You have a great idea.
You write it up.
You send it to a journal.
The journal editor looks at it and says,
well, this might be okay.
Let's, let's find out.
Then they select three or four people
to send your paper to.
Maybe I get the paper
and you and I are friends,
but like we're actually competing.
Now look at the paper.
I go, oh my God, she has a good idea.
And then I, then I write
all kinds of like reasons
why it's a, it's a bad idea.
Oh my, it's like an experiment
in human nature
and everything that's bad about it.
Well, no, okay.
Just in defense of this,
it's not necessarily bad.
Like most ideas,
when a scientist thinks
they have a good idea,
they're almost always wrong.
That's fair.
By the way, that's fair.
So you want their colleagues
to like hold them to account.
So peer-review by itself
is not necessarily,
it's a good thing, actually.
It's actually a good thing, right?
So I send this to the editor.
I send a letter that says,
here are the things I love,
the checks I'd like to see on the idea
before I recommend publication.
That editor sends the list to you.
Then you like sit there and like yell it.
You don't know who I am
because it's anonymous,
but you're like,
who is this reviewer number two
and why are they making my life miserable?
And you do all the hundred different checks.
This is peer review at its best.
You revise the paper.
You, you make it better.
You try to address all the criticisms,
revise it,
and then eventually the editor might accept it.
That's peer review at its best.
Peer review at its worst
is what you just said, right?
It's like some,
I see your paper,
I'm jealous of you.
I said, reject the paper
and you don't even know I said it.
Or the editor looks at your claim,
realizes it has some political impact
that they don't like
and they just reject it out of hand.
Right, well, that's what I'm worried about,
the group thinking,
the consensus thinking.
So it's not transparent, right?
Nobody sees the peer reviews
other than the editor and you.
The public doesn't see it.
They just see the finished paper, right?
And there's no way to know
if the peer review process was good.
Now, some journals have a great reputation,
but they, so, you know,
so like they're highly ranked.
And so you assume the peer review
has none of that problems in it,
but that's just not true.
That's a lot of power
to whoever the editor is.
Why isn't that transparent?
Why can't we see the peer's reviews?
I don't have an answer to that question.
I think we should.
But let me step back.
Fundamentally, the question is,
it's not even about peer review.
It's how do you decide
what is true in science, right?
It's a big fancy word, epistemology, right?
How do you decide
who has the epistemological power, right?
So the first scientific revolution,
the big scientific revolution
of the Galileos of the world, right?
What was at issue there
was whether ecclesiastical authorities
had the power to decide
what was true or false in physical matters.
Do the moons of Jupiter move, right?
And the first scientific revolution said,
no, no, the ecclesiastical authorities
don't get to decide that.
Clever people with telescopes
get to decide that.
If you look at the moons of Jupiter,
you see they move, then they move.
And no matter what anybody says,
they move, right?
Because you can see
with the telescope that they move.
Essentially, it was a democratization
of the power to determine
what was true or false
in matters of physical reality, right?
That's the first scientific revolution.
What we have now is a situation,
exactly what you said.
A relatively small number of people,
powerful people,
get to decide what was true or false in science.
Does the COVID vaccine
stop you from getting and spreading COVID?
I can see and you can see that it doesn't,
but it's a peer-reviewed journal
that says that it does.
I mean, so now it does
because society has to admit that it does
because the high ecclesiastical
scientific authority got to decide, right?
Instead of the scientific reality,
which is that the COVID vaccine
doesn't stop you
from getting and spreading COVID, right?
So the problem then is the epistemological one.
Why is it that a relatively small number of people
in a very non-transparent way
get to decide for all of society
what's true or false about physical reality?
And then you add that on top of that,
then there's all kinds of other things
that are added on on top of it, right?
So there's scientific reality,
and then what do you do with that fact?
Those are often personal preferences, values.
There's all kinds of other trade-offs
that you care about.
And scientists that get to decide empirical truth
don't necessarily have a lot of expertise
in those areas,
and yet they often step into those areas, right?
So you have top scientific journals
making recommendations
who should be president.
Well, their scientific authority doesn't tell you
who should be president, right?
So they're using the epistemological power they have
to trespass in areas of things
that are of tremendous import to people
that they have no expertise in.
Yeah.
Well, it is our fault
that we have given them that power
because as we know human nature,
I mean, you're a Christian,
we know that if we give people so much power,
ultimately it will corrupt them.
The solution is very possibly
just take away some of their power
and provide more visibility.
The genius of it is that no one gets to decide,
the power is dispersed pretty broadly.
There's checks and balances all across
the American system.
You need the same thing in science.
Yes.
But of course, there's expertise, right?
That does matter.
Like there is that you,
I mean, people spend decades
trying to build up the expertise
so they can have these ideas
that might advance health.
So you have to figure out a way
to set up structures
that allow there to have that expertise
and for that expertise to matter,
but there'd be checks.
Peer review is one of them
and it's good, but it's not perfect.
Even more fundamental is this idea of replication.
Yes.
Right?
So I have a great idea.
I go through peer review,
I publish it,
it's in some fancy journal
and you look at it and you say,
that seems too good to be true.
And so you do your own study
and you collect your own dataset
and you test the idea
from an independent point of view.
You find out you don't agree with me.
Well, that means that my idea isn't true.
Even though I'm the fancy director of the NIH,
even though I published in a top journal,
it doesn't matter because
when you double-check my work in good faith,
you found that it didn't agree with it.
It's called replication
because you can't replicate the same results.
Right.
Sometimes it's called reproducibility.
Does the result generalize to other populations?
There's a fancy word for the consilience, right?
Other people looking at the same idea
or similar idea tend to find the same thing.
Is that required in peer reviews and studies?
It is not required to replicate the results
in order to prove that it is in fact true.
That's right.
So in peer review,
I've done, again,
thousands of peer reviews in my life.
Basically never is it the case
where the editor sends me the data
from the paper to replicate it.
Not required to do that.
Wow.
Okay, we have to talk about some good things too.
No, but let me tell you how we're fixing this.
Okay, tell me how we're fixing this.
Because I'm like, ah!
No, so the reason why we have this replication crisis,
and it is a crisis, right?
It's a crisis.
I'm shocked.
Right, so just to flash out the crisis
before I tell you the solution.
We have in cancer biology, in psychology,
in field after field after field,
you find that the papers published in top journals,
when independent people look at the same thing,
often they can't even begin to replicate it
because the methods aren't described clearly,
the data sets aren't available,
the tissue samples aren't available.
And so 60% of the time, 70% of the time,
the published biomedical research literature
is not reliable.
It's not replicable.
Would they argue that they don't have the funding
to also create another study to replicate it?
Yes.
Maybe they would say that too.
They would absolutely say that.
So that's how we're fixed.
When it fixes, you have to do multiple things.
We're doing all of those things.
So first, we're going to start funding people
to do replication work.
It's really important that people get the recognition
of a large NIH grant saying,
look, you're a valued person in scientific society.
We need you.
That replication work is not as sexy
as the new discovery at least from Nobel Prize,
but it's absolutely fundamental
for the checks and balances.
So we're going to start funding researchers to do it.
In fact, we're funding researchers
to do replication work.
Second, we're going to make replication an honor.
So right now, if you say,
Jay, I'm going to replicate your idea,
I'm going to view you as a threat.
What if you find I'm wrong?
I'm going to lose status, right?
But in reality, it's an honor.
If I have an idea that's important enough
for you to want to replicate,
that means I have an important idea.
That should be seen as you're doing me an honor
by attempting to replicate my idea,
whether you replicate it or not,
or find the same thing as not.
Just identifying my idea as worthy
of replication is an honor.
So Einstein is Einstein
because Eddington looks at the transit of Mars
and says, oh yeah, relativity works, right?
So that replication then is the core reason
why Einstein is successful,
not just his math and genius, right?
It's the replication that mattered.
Well, and you're reflecting a double investment
in their idea because the NIH is not just funding you,
but it's double funding you.
Yeah, and so we can have the scientific community
rather than the government decide
what ideas are worthy of the honor of replication, right?
So that's two, and then three,
we're gonna have a journal, an NIH journal
where you can publish your replication ideas.
It's hard to publish your replication ideas,
it's just hard, much easier
to get your new ideas published.
But we'll have a high profile,
prestigious scientific journal
where the peer reviews for the replication
are made public alongside the papers.
So it's completely transparent.
And then three, when you search for papers,
instead of highlighting what journal it's published in,
we'll highlight all the other papers
that have looked at the same idea.
This is why AI comes in,
you can see at a glance what other papers are seeing
and you can decide for yourself,
is this idea something I should believe?
And then finally, we'll have these metrics,
kind of like baseball,
you have home runs and batting average and all that.
We'll have lots of metrics that reward scientists
for having ideas that are replicated,
for sharing their data, sharing their code
and acting in ways that are good for science
instead of just, do I get a lot of publications?
If you do all those things, you revolutionize science.
How is America doing in comparison
to other countries around the world
when it comes to innovation?
I generally associate us with cutting edge,
we are certainly paying for medicines
for others around the world to be invented.
I know that you and President Trump
have already dealt with the issue
that Americans are paying more for prescription drugs
in America than in Europe and other countries
and thank you for that
and thank you for taking some of the shouldering
that we have seen over the past few years
when it comes to medicines.
But I'm curious when it comes to medical innovations,
how do we look in comparison to other countries?
Well, the US, in large part because of the NIH
and biomedical research is still the number one country
in the world in biomedicine and biomedical research.
The Chinese are a real challenger to us.
They've just grown very, very rapidly
in part because of American investments in the Chinese.
Almost every single biomedical researcher of note in China
received NIH money in the past.
Maybe they studied in the United States
and went back to China.
The US has invested heavily in the success
of the Chinese biomedical research enterprise.
We're gonna start investing more in Americans now
and have been.
And I think the kind of innovative
and genius and capacity of Americans
to do this kind of research
that leads to better health and outcomes
I think belongs in the United States.
It does matter that we work
with our international colleagues.
It's not true that the only good ideas happen
in the United States in science.
They happen elsewhere.
So we wanna make sure we allow that collaboration.
But we wanna invest in Americans
and wanna make sure that the investments we make
are of value to Americans.
The United States still remains the number one place
in the world to do biomedical research.
It's still the most,
even though with all the problems we've been talking about,
still the most innovative in the world.
And I'm really high on our future actually
because I think that with these reforms
that we've put in place at the NIH,
we'll have another century of tremendous success.
Yeah, they sound almost simple.
They sound like simple,
just common sense things that need to be done.
So hopefully that's easy enough.
Can you share with us some details
about some of the research that you've come across
while you've been here for about 15 months
and maybe even before?
Every single one of us knows
somebody battling with cancer.
So we read on the internet and we go on podcasts
instead of reading peer-reviewed journals,
which is a problem, but you're fixing this
so we can start actually relying on institutions
with experts who are trustworthy.
But online, you'll hear things like ivermectin,
high-dose vitamin C, fenbendazole,
menbendazole,
forgive me if I'm not pronouncing these things correctly.
I've asked our audience to send in some questions
in advance of me sitting with you.
And they have some questions about innovation in cancer.
Can you point us in a logical direction?
Yeah, so there's been,
first, in cancer specifically,
there's been tremendous advances
over the last three, four decades.
Like things that look to me like science fiction.
If you asked me when I was a medical student
30 some years ago,
whether it would be possible to have what we have,
I would just say, no way.
You see, actually, a decrease in cancer mortality
over the last three decades.
A huge decrease in cancer mortality.
There's little talked about.
Now, partly that's due to better screening.
Mm-hmm, early detection.
You mentioned that the reforms I'm talking about are simple.
It's a very simple thing, and yet it saves lives, right?
So early detection matters.
And so we have tools for better early detection
that didn't exist,
that are more accurate than they were before.
They make it easier to get screened.
And so that's true.
But also partly because we have new treatment modalities.
When I was a medical student in the 90s,
the idea of using immunotherapy to treat cancer
was seen as science,
just no way it could possibly work.
Because one of the things cancer cells do
is they trick your body into thinking
they're your own cells.
So why would your immune cells attack it?
Right, your immune cells are designed
to not attack your own cells, right?
The autoimmune disorders or disorder of that system.
And so cancer cells would trick your immune systems
not to attack it.
Now we have treatments that are not chemotherapy,
that are not radiation.
The body is trained to identify cancer cells,
the immune function, to identify cancer cells
and not attack the rest of the body.
And it's just incredibly promising.
And that's for cancer.
There are other diseases that are not cured
that I thought would never be cured.
Genetic conditions like sickle cell anemia,
conditions like cystic fibrosis.
But cystic fibrosis, when I was a medical student,
what I was taught was that a patient with cystic fibrosis
is gonna, you know, you get like lung infections,
you cough all the time.
It's really, it's a terrible condition.
And you would die in your teens or 20s.
Now with advances based on basic fundamental knowledge
and then careful clinical trials,
there are drugs that will allow you to live
a full, healthy life with cystic fibrosis.
The sickle cell anemia cure, it's miraculous.
There's this gene editing technology.
Sickle cell anemia, you know,
it's like especially African-American kids
that tend to have this, they get clotting
because your red cells are like misshapen
and they end up in the hospital over and over again
all through their youth.
It's really sad actually.
These genetic editing of the stem cells
of the produced red blood cells
will allow people to be cured of sickle cell anemia.
So they never have those.
The major problem now, and you brought up drug pricing,
is that those treatments cost
millions and millions of dollars.
Why?
Well, they're complicated to make.
So in order to do this, in order to stick with sickle cell,
we have to take the cell, a stem cell out of the child.
Then you have to edit it, gene edit it.
You have to like then remove all the other stem cells
in the body and re-inject the stem cells
that are edited to fix the one little genetic error
that causes sickle cell anemia.
It's very individualized.
It's really expensive.
So I'm investing in research
to actually reduce the price of that treatment.
Imagine if sickle cell anemia,
instead of the treatment costing $3 million,
instead it costs $300 for the treatment.
There'd be no more sickle cell anemia on earth.
Which by the way, sickle cell anemia is an example
of how race should be viewed
when actually studying a disease.
As opposed to DEI, this is actually scientific.
Yeah, well, I think race and sex matter for our health.
Especially men and women are fundamentally different
in some ways, common biology in many ways.
If you don't account for these things
when you're doing your biology or your research,
then you're not really doing science right.
That's different than ideology, right?
Some ideological approaches to scientific matters
never produces actual advances in reality
because they're not reality.
You have to take reality into account.
You mentioned vaccines.
I can't sit here with you and not ask you
about the 72 vaccines that are recommended
and sometimes enforced in certain states for children.
Do you have any general thoughts
on how a parent should think about these vaccinations?
Well, just, I mean, from a high level,
I think many of the key childhood vaccines
are really essential for child health.
Now, no vaccine is perfect, right?
When you are recommending that millions,
hundreds of millions of people take a product,
even if you have a low probability of side effects,
like 0.001% or something,
you're still gonna get some people who are injured, right?
So it's true of every medicine.
There's always a benefit or harm of every medicine
and doctors, good doctors will tell you that
and try to reduce the risk, the probability of the harm
and then address that harm if it tends to happen.
You make good decisions by understanding
that there's always a trade-off, right?
So here you have a product,
let's say the measles vaccine, the MMR vaccine,
that is, that I think has saved countless kids.
Really important to take
and yet sometimes it can cause harm.
I think rarely, there's lots of fights over how rare,
but I think rarely it can cause harm.
We have an obligation to help the people who it harms
while still nevertheless recommending
for the vast, vast majority of the population
that this is a worthwhile product.
That's because there's lots of,
and you have to be careful research
and it has to be replicated.
You can't treat it like a religion.
It has to be subject to normal science.
But there is like controversy about some vaccines, right?
So like I've been talking about the COVID vaccine.
I think for most people, especially kids,
it's not necessary.
Maybe if you're immunocompromised and old now,
I don't know, maybe it's necessary.
But again, that's benefit-harm,
individual assessment, informed consent.
All of those I think are how you build trust in vaccines.
It's not going to be a universal take it or else
because then you have no trust.
Right, that's exactly the problem.
Now people think that all the 72 vaccines
are just deadly and horrible
because one or two people who spoke about it truthfully
have been harassed, called vaccine deniers,
all kinds of names.
The name calling has not been helpful
and it just feels like we didn't have
enough transparency in understanding.
The other question I have, Jay,
is there have been vaccines that have been mandated
for many, many years.
Polio, for example.
Vaccines that seem to have cared for diseases
that may have been eradicated.
Now they may return.
I'm not saying they may not return.
I'm sure you would have better knowledge than me.
But why not, if polio returns,
why not then call on the nation
to then vaccinate their children for polio?
Why do we need to give our children vaccinations
for diseases that don't exist anymore in our lifetime?
That's a great question.
So a disease like smallpox,
which actually has been eradicated.
The last case of smallpox I think that was in the wild
was like 1979.
We no longer recommend anyone get the smallpox vaccine
unless you're like some military personnel
or because of fear of German warfare or something, right?
For a lot of these conditions,
the vaccines are quite successful
in reducing the prevalence.
When a population is 95 plus percent vaccinated
against the measles vaccine,
measles doesn't float around.
But as soon as it gets to 90%, 85%,
you start seeing measles cases again.
That's what we've seen in the last year or two,
two years actually, two, three years
is you've seen this big uptick
in all over the world in measles vaccine.
In measles, because the percent of people
vaccinating their kids against measles
collapsed during the pandemic
because people lost trust in all vaccines,
even ones that I think are important.
So things like that can come back
if the population is not sufficiently protected.
If you're successful, you see low prevalence,
almost no cases.
And you say, okay, well, we don't need it anymore.
But until it's eradicated, it can come back.
Now, some of these conditions,
you can't eradicate them
because they have other reservoirs.
Smallpox was special
because only humans could be infected with it.
No animals were infected with smallpox.
And you had a vaccine
that could stop the spread of it.
And so you had a chance of eradicating it.
Many of these are just, they're permanent.
Now, you brought up the 72, right?
Different countries have different schedules
of recommended vaccines.
Many countries where you have
high vaccination coverage,
they don't mandate vaccines.
Like in Scandinavia, they don't mandate vaccines.
They get 95 plus percent uptake
because people trust public health there.
And they have a more limited schedule.
The problem in the United States
is you have a lot of vaccines on a schedule
and the American public,
especially post-pandemic,
don't trust public health recommendations anymore.
So one of the things we did with Secretary Kennedy
is we shifted the recommendation
to something more like a European schedule,
the recommendations.
It still maintains some of the most,
all the essential vaccines,
MMR, DPT, all these essential vaccines
that are on our recommended list.
And yet we're getting grief
because, oh, well, you can't just assume
that Americans will just accept a Danish schedule
because people of Denmark
are much more sophisticated than Americans, right?
Well, I reject that.
I think that the people of the United States
are certainly capable of valuing evidence
as well as the Danish population can.
The problem we have now
is that American people don't trust public health
and public health in many cases
doesn't don't trust the American people.
We have to fix that.
That starts by the public health authorities
and I'm the acting director of the CDC.
I say this just bluntly.
I think by public health authorities
trusting the American people to do the right thing,
you build this reciprocal trust relationship
that results in the right thing happening.
It's so true.
And it would be a win-win for all of us
because now you see many people
buy random things on the internet.
I mean, I don't know what you think about peptides
and I don't know if it's even within your purview,
but I will say that there is something interesting
worth looking at.
And many of the people
who don't want to vaccinate their kids
or don't want to take vaccines
or against many of the pharmaceuticals
buy random things on the internet,
including peptides,
and they put those things in their bodies.
And those things are not only not peer-reviewed,
I don't know who's even reviewing these things.
And so you're coming up with another set of anarchy
within medicine.
And I could imagine that should be pretty concerning
to all of us, right?
We do need to rebuild our trusted institutions.
We do need the institutions to trust us,
the American people,
that if you do right by us,
we will trust you again
because we need to trust you.
Yeah.
Well, on peptides specifically,
I mean, I think it's going to be complicated, right?
Peptides are like, I think like protein compounds
that are like 49 amino acids or fewer.
And so that means there's like lots
of different possible combinations.
And so that means each one
may have a different biological effect.
So you have to assess them separately.
You can't just say peptides generally as a class.
The regulatory structures around them,
and the FDA is responsible for this,
are looser than I think for other products.
And so you're going to get lots of people
who just have strong feelings about them
without having a lot of the sort of...
And now at the same time,
I kind of understand that the president's
a big believer in right to try.
Yeah.
Right?
And so I think that's not unreasonable.
If you have a product that you're pretty sure is safe,
then let people try it and see if it works for them.
Often you get this heterogeneous outcome
where for some people square by
and some people say,
well, it doesn't do anything for me, right?
I think a lot of the peptides are like that.
Yeah, makes total sense.
Final question.
If you end up looking back 20 years from now,
what do you think would be a real success story?
Something that is something
you'd be really, really proud of
if you achieved here as the director of the NIH?
Well, I think I want to achieve the NIH mission.
I think it's an incredible mission, right?
Support biomedical research
that improves the health and longevity of people.
And so 20 years from now,
we look back and say the research
that the NIH funded under my watch,
the structures we put in place
for the incentives to get it right,
improve people's health,
reverse the longevity flatlining that we've seen.
We started to see people living longer,
living healthier,
having more fulfilling lives.
That's the measure.
That's the true measure of success,
I think, from this job.
Well, we want you to be successful, Dr. Jay.
So God bless you
and thank you for everything that you do for our nation
and by extension, the world.
Thank you so much for your time.